New York, NYNCT05838391Now EnrollingIRB Ready

Anal Squamous Cell Carcinoma Clinical Trial in New York, NY

Access cutting-edge anal squamous cell carcinoma treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.

Sponsored by Columbia University

Quick Self-Assessment

See if you qualify for this New York location

Preparing your pre-screening questions…

Expert Care in New York

Access anal squamous cell carcinoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related anal squamous cell carcinoma treatment provided free

Apply for This New York Location

Check if you qualify for this anal squamous cell carcinoma clinical trial in New York, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New York

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New York site if eligible
  4. 4Begin participation

About This Anal Squamous Cell Carcinoma Study in New York

This is a 20 patient pilot study to examine the feasibility of dose-adapted radiation therapy for the treatment of locally advanced anal squamous cell cancer. The tumor and a patient's anatomy may change during radiation treatment and daily adaption of the radiation plan (i.e., a new daily plan based on the anatomy of the day) may help to maximize the dose to the tumor and minimize the radiation dose to the normal surrounding organs.

Sponsor: Columbia University

Who Can Participate

Inclusion Criteria

Histologically proven, invasive primary squamous, basaloid or cloacogenic carcinoma of the anal canal.
American Joint Committee on Cancer (AJCC) 8th edition stage T2 \> 4 cm, T3-4 or N1.
Age ≥18 years.
Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (Karnofsky ≥60%).
Life expectancy of greater than 12 months.
Patients must have normal organ and marrow function as defined below:
leukocytes greater than or equal to 3,000/microliter
absolute neutrophil count greater than or equal to 1,500/microliter
platelets greater than or equal to 100,000/microliter
total bilirubin within normal institutional limits
Aspartate transaminase (AST)(SGOT)/Alanine transaminase (ALT)(SGPT) ≤ 2.5 × institutional upper limit of normal
creatinine within normal institutional limits OR creatinine clearance ≥60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal.
Females of childbearing potential and males must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 6 months after completion of study therapy. All pregnancies must be reported.
Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria

Prior or co-existing invasive malignancy (except non-melanomatous skin cancer) unless disease free ≥ 2 years.
Prior chemotherapy or radiation for anal cancer.
Patients who have undergone complete surgical resection.
Presence of recurrent/metastatic disease.
Prior allergic reaction to 5-Fluorouracil or mitomycin C.
Artificial organ prosthetics, pacemakers or other implantable devices.
Prior radiotherapy to the pelvis that would result in overlap of radiation therapy fields.
Uncontrolled inter-current illness including but not limited to known history of HIV with cluster of differentiation 4 (CD4) count less than 200 or symptomatic cardiac disease.
Women who are pregnant or lactating.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New York?

Yes, this clinical trial (NCT05838391) has an active research site in New York, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Anal Squamous Cell Carcinoma Treatment Options in New York, NY

If you're searching for anal squamous cell carcinoma treatment options in New York, NY, this clinical trial (NCT05838391) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced anal squamous cell carcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Ready to Join in New York?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New York, NY